TRPM8 antagonist 4
TRPM8 antagonist 4 is a CB2R partial agonist (EC50=54.2 nM, Ki=3.2 μM) and TRPM8 antagonists (IC50=42.3 nM) with high functional selectivity and good physicochemical properties. TRPM8 antagonist 4 has significant anti-inflammatory and analgesic effects and good safety, reduces the mRNA expression of TNF-α, IL-6, and IL-1β.
For research use only. We do not sell to patients.
- CAS No.: 3107363-68-5
- Formula: C20H27NO3
- Molecular Weight:329.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TRPM8 42.3 nM (IC50) |
CB2R 54.2 nM (EC50) |
CB2R 3.2 μM (Ki) |
IL-6 |
IL-1β |
TNF-α |
In Vitro
TRPM8 antagonist 4 (Compound 6b) exhibits neither antagonistic nor agonistic activity at the CB1R in the HTRF cAMP assay[1].
TRPM8 antagonist 4 (1 nM-1000 nM) inhibits hTRPM8 currents induced by 30.0 μM menthol in HEK293 cells, with IC50=42.3 nM[1].
TRPM8 antagonist 4 (1 μM-1 M) binds to CB2R by radioligand competition assay[1].
TRPM8 antagonist 4 (0.3 μM, 8h) reduces the mRNA expression of TNF-α, IL-6, and IL-1β in LPS-stimulated RAW264.7 macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS (HY-D1056)-stimulated (100 ng/mL, 8 h) RAW264.7 macrophages
-
Concentration:0.3 μM
-
Incubation Time:8h
-
Result:Reduced the mRNA expression of TNF-α, IL-6, and IL-1β compared to LPS-induced model group.
Were comparable to those of CBG at the same concentration the inhibitory effects of on pro-inflammatory cytokine mRNA expression.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUClast |
|---|---|---|---|---|---|---|
| Mice | 25 mg/kg | p.o. | 3.6 h | 0.3 h | 39.0 ng/mL | 61.7 ng·h/mL |
In Vivo
TRPM8 antagonist 4 (Compound 6b) (2.5 mg/kg, i.p., once) shows anti-inflammatory effects in LPS (HY-D1056)-induced inflammation in C57BL/6J mice model[1].
TRPM8 antagonist 4 (5 mg/kg, i.p., once) exhibits pronounced analgesic effects in the Acetic acid (HY-Y0319)-induced in C57BL/6J mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS (HY-D1056)-induced (i.p., 0.5 mg/kg) inflammation in C57BL/6J mice[1]
-
Dosage:2.5 mg/kg
-
Administration:i.p., once
-
Result:Suppressed LPS-induced increases in serum IL-6, TNF-α levels.
-
Animal Model:The Acetic acid-induced (i.p., of 1% acetic acid, 10 mL/kg) in C57BL/6J mice[1]
-
Dosage:2.5 mg/kg, 5 mg/kg
-
Administration:i.p., once
-
Result:Reduced the number of writhing, prolonged the latency to the first writhing at a concentration of 5 mg/kg.
Chemical Information
-
CAS No. 3107363-68-5
-
Molecular Weight 329.43
-
Formula C20H27NO3
-
SMILES
O=C(N)C1=C(O)C=C(OC/C=C(C)/CC/C=C(C)/C)C=C1C2CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)